BioRegenx, Inc. (BRGX)
| Market Cap | 8.94M -41.6% |
| Revenue (ttm) | 1.77M -23.4% |
| Net Income | -1.30M |
| EPS | -0.00 |
| Shares Out | 971.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,500 |
| Open | 0.0076 |
| Previous Close | 0.0076 |
| Day's Range | 0.0076 - 0.0076 |
| 52-Week Range | 0.0075 - 0.0300 |
| Beta | -2.87 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About BioRegenx
BioRegenx, Inc. engages in the research, development, and commercialization of dietary supplements, medical devices, software, and contactless diagnostic technologies in the United States and internationally. The company offers DocSun AI engine, which integrates with a ballistocardiograph that detects an individual's heartbeat; TruScan.AI mobile app for additional health indications; VitalWellness app for DNA and epigenetics platform; and Endocalyx Pro, a dietary supplement targeting microvascular capillary health. It also provides MyBodyRx, a ... [Read more]
Financial Performance
In 2025, BioRegenx's revenue was $1.85 million, a decrease of -20.75% compared to the previous year's $2.34 million. Losses were -$1.54 million, -93.30% less than in 2024.
Financial StatementsNews
BioRegenx, Inc. Engages Sichenzia Ross Ference Carmel LLP for Legal Representation in Connection with Planned Uplisting to National Stock Exchange
CHATTANOOGA, TENNESSEE / ACCESS Newswire / May 13, 2025 / BioRegenx, Inc. ("BioRegenx" or the "Company") (OTC Pink:BRGX), a health technology company advancing microvascular and metabolic health throu...